CVA
MCID: CRB039
MIFTS: 65

Cerebrovascular Disease (CVA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease 12 54 15
Cerebrovascular Disorders 44 70
Cerebrovascular Accident 12 70
Cerebrovascular Disorder 12 17
Stroke 12
Cva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6713
ICD9CM 34 437.9
MeSH 44 D002561
NCIt 50 C2938
SNOMED-CT 67 266312006
UMLS 70 C0007820 C0038454

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 and moyamoya disease 1, and has symptoms including seizures, tremor and back pain. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Folate Metabolism. The drugs Clopidogrel and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2213)
# Related Disease Score Top Affiliating Genes
1 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 32.6 SERPINA3 NOTCH3 HTRA1 COL4A1 APP APOE
2 moyamoya disease 1 32.5 NOTCH3 MTHFR CRP ACTA2
3 aspiration pneumonitis 32.5 SERPINA3 CRP
4 vascular dementia 32.4 SERPINA3 NOTCH3 MTHFR CRP APP APOE
5 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 32.4 NOTCH3 HTRA1 CRP
6 stroke, ischemic 32.3 SERPINA3 SELP NOTCH3 MTHFR CRP APOE
7 peripheral artery disease 32.3 SELP CRP APOE APOB APOA1 ACE
8 intracranial berry aneurysm 32.2 SERPINA3 CRP APOE
9 retinal vascular occlusion 32.2 SELP MTHFR CRP
10 col4a1-related familial vascular leukoencephalopathy 32.0 NOTCH3 HTRA1 COL4A1
11 carotid stenosis 31.9 SELP MTHFR CRP APOE ACE
12 transient cerebral ischemia 31.9 NOTCH3 MTHFR ACHE
13 supranuclear palsy, progressive, 1 31.9 SERPINA3 APP APOE ACHE
14 anxiety 31.6 CRP APP APOE ACHE ACE
15 vascular disease 31.6 SELP MTR MTHFR MIR21 CX3CR1 CRP
16 mild cognitive impairment 31.6 MTHFR APP APOE ACE
17 dementia 31.5 SERPINA3 NOTCH3 HTRA1 APP APOE ACHE
18 acute cystitis 31.5 SERPINA3 CRP ACE
19 homocysteinemia 31.5 MTR MTHFR CRP APOE
20 coronary heart disease 1 31.4 CX3CR1 CRP APOE APOB APOA1 ACE
21 disease of mental health 31.4 SERPINA3 SELP NOTCH3 MTR MTHFR MIR21
22 migraine with or without aura 1 31.4 NOTCH3 MTHFR CRP COL4A1 ACE
23 hypercholesterolemia, familial, 1 31.4 CRP APOE APOB APOA1 ACE
24 peripheral vascular disease 31.4 SELP MTHFR CRP APOB APOA1 ACE
25 intracranial embolism 31.4 SELP CRP ACE
26 alzheimer disease 31.4 SERPINA3 MTR MTHFR APP APOE APOA1
27 sleep apnea 31.3 CRP APOE APOB ACE
28 aortic valve insufficiency 31.3 CRP ACTA2 ACE
29 lipid metabolism disorder 31.3 CRP APOE APOB APOA1 ACE
30 atherosclerosis susceptibility 31.3 SELP MTHFR CX3CR1 CRP APOE APOB
31 cerebral amyloid angiopathy, cst3-related 31.3 SERPINA3 APP APOE
32 carotid artery disease 31.2 SELP CRP APOE APOB APOA1 ACE
33 arteries, anomalies of 31.2 SERPINA3 MIR21 CRP APOE APOB APOA1
34 hydrocephalus 31.2 SERPINA3 MTHFR APP APOE ACE
35 angina pectoris 31.2 CRP APOA1 ACE
36 macular degeneration, age-related, 1 31.2 SERPINA3 HTRA1 CX3CR1 CRP APOE APOB
37 arteriosclerosis 31.2 SELP MIR21 CRP APOE APOB APOA1
38 patent foramen ovale 31.1 NOTCH3 MTHFR CRP COL4A1 ACE
39 mitral valve disease 31.1 SERPINA3 CRP AGTR1 ACE
40 osteoporosis 31.1 MTHFR MIR21 CRP APOE APOB ACE
41 microvascular complications of diabetes 3 31.1 MIR21 AGTR1 ACE
42 normal pressure hydrocephalus 31.1 SERPINA3 APP APOE ACE
43 cerebral atherosclerosis 31.0 SERPINA3 MTHFR CRP APOE APOB APOA1
44 spastic hemiplegia 31.0 MTHFR COL4A1
45 deficiency anemia 31.0 SERPINA3 SELP MTR CRP ACE
46 binswanger's disease 31.0 NOTCH3 APP APOE ACHE
47 aspiration pneumonia 31.0 SERPINA3 CRP ACE
48 lipoprotein quantitative trait locus 31.0 SERPINA3 SELP MTR MTHFR MIR21 CX3CR1
49 migraine with aura 31.0 NOTCH3 MTR MTHFR ACE
50 syphilis 31.0 SERPINA3 CRP ACE

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 38)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Chronic Kidney Disease Decubitus Ulcer
Deficiency Anemia Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Esophagitis
Familial Atrial Fibrillation Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypertensive Encephalopathy Hypothyroidism
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Labyrinthitis Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


seizures; tremor; back pain; angina pectoris; chest pain; headache; syncope; edema; pain; chronic pain; sciatica; vertigo/dizziness; equilibration disorder; sleeplessness; transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Cerebrovascular Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ACE ACHE ACTA2 AGTR1 APOA1 APOB
2 homeostasis/metabolism MP:0005376 10.03 ACE ACHE AGTR1 APOA1 APOB APOE
3 muscle MP:0005369 9.56 ACHE ACTA2 APOB APOE APP COL4A1
4 vision/eye MP:0005391 9.36 ACE ACHE ACTA2 APOB APOE COL4A1

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 730)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
3
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
4
Nadroparin Approved, Investigational Phase 4
5
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
6
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
7
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
8
Galantamine Approved Phase 4 357-70-0 9651
9
Amlodipine Approved Phase 4 88150-42-9 2162
10
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
11
Losartan Approved Phase 4 114798-26-4 3961
12
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
13
Atorvastatin Approved Phase 4 134523-00-5 60823
14
Dipyridamole Approved Phase 4 58-32-2 3108
15
Edaravone Approved, Investigational Phase 4 89-25-8 70335
16
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
17
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
18
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
19
Pantoprazole Approved Phase 4 102625-70-7 4679
20
Atenolol Approved Phase 4 29122-68-7 2249
21
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
22
Dobutamine Approved Phase 4 34368-04-2 36811
23
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
24
Dronedarone Approved Phase 4 141626-36-0, 141625-93-6 154087
25
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
26
Tizanidine Approved, Investigational Phase 4 51322-75-9 5487
27
Triflusal Approved, Investigational Phase 4 322-79-2
28
Saxagliptin Approved Phase 4 361442-04-8 11243969
29
Flecainide Approved, Withdrawn Phase 4 54143-55-4 3356
30
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
31
Propafenone Approved Phase 4 54063-53-5 4932
32
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
34
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
35
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
36
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
37
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
38
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
39
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
40
Ticlopidine Approved Phase 4 55142-85-3 5472
41
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
42
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
43
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
44
Nitroprusside Approved, Investigational Phase 4 15078-28-1 11963622
45
Labetalol Approved Phase 4 36894-69-6 3869
46
Nitric Oxide Approved Phase 4 10102-43-9 145068
47
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
48
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
49
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
50
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 5617)
# Name Status NCT ID Phase Drugs
1 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
2 Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke Unknown status NCT01198496 Phase 4 Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
3 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
4 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
5 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
6 Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
7 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
8 SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial Unknown status NCT02004509 Phase 4 anticoagulant by physician criteria
9 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
10 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
11 Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident Unknown status NCT02714478 Phase 4
12 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
13 A Double-blind Randomized Trial to Compare the Efficacy of Intermittent Pneumatic Compression (IPC) With and Without Early Anticoagulant Treatment for Prevention of Venous Thromboembolism (VTE) in Patients With Acute Primary Intracerebral Hemorrhage (ICH) Unknown status NCT00699465 Phase 4 enoxaparin;enoxaparin placebo
14 A Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the Effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy (DAPT) in Subjects Undergoing Percutaneous Coronary Intervention With the CYPHER® Sirolimus-eluting Coronary Stent (CYPHER® Stent) Unknown status NCT00954707 Phase 4 Clopidogrel & Aspirin, Prasugrel & Aspirin;Placebo & Aspirin
15 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Unknown status NCT01444508 Phase 4 Ringer-lactate "SAD";HES 130/04
16 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
17 Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
18 Research Assistant Doctor Unknown status NCT03860662 Phase 4 Botox;Baclofen
19 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
20 TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT Unknown status NCT03529149 Phase 4
21 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Unknown status NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
22 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
23 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
24 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
25 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
26 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
27 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
28 Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke Unknown status NCT03686163 Phase 4 Nerve Growth Factors;normal saline
29 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
30 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
31 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
32 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
33 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
34 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
35 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
36 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
37 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
38 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
39 Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling Unknown status NCT02224131 Phase 4 Aspirin and clopidogrel;Aspirin and clopidogrel
40 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
41 Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study Unknown status NCT02817503 Phase 4 Standard BP control;Moderate BP control;Intensive BP control
42 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
43 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
44 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients Unknown status NCT02484027 Phase 4 Rosuvastatin
45 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
46 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
47 Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO Unknown status NCT01550588 Phase 4 Standard medical treatment
48 Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing the Antispastic Efficacy and Safety of Dynamic Night Hand Splinting in Adults With Post-stroke Hemiplegia Treated by Botulimum Toxin (Dysport®) - (a Pilot Study) Unknown status NCT02888548 Phase 4
49 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
50 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: cerebrovascular disorders

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

40
Brain, Endothelial, Bone, Cortex, Kidney, Bone Marrow, Spinal Cord

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 17873)
# Title Authors PMID Year
1
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 54 61
20485689 2010
2
Acetazolamide improves cerebral hemodynamics in CADASIL. 61 54
20227091 2010
3
The angiotensin II type 2 receptor in the brain. 54 61
19861353 2010
4
Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). 61 54
20028534 2009
5
APOE-related mortality: effect of dementia, cardiovascular disease and gender. 54 61
18237822 2009
6
Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. 54 61
19200547 2009
7
Observation of the density and size of cells in hippocampus and vascular lesion in thalamus of GFAP-apoE transgenic mice. 61 54
19633698 2009
8
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. 61 54
19417859 2009
9
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. 54 61
18985627 2009
10
CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene. 61 54
19006080 2009
11
Report of two Chinese families and a review of Mainland Chinese CADASIL patients. 61 54
19167727 2009
12
MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. 54 61
19139365 2009
13
Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. 54 61
19542606 2009
14
Age and apoE associations with complex pathologic features in Alzheimer's disease. 54 61
18653200 2008
15
Association of apolipoprotein E genotype and cerebrovascular disease risk factors in a Turkish population. 61 54
18576210 2008
16
Cystatin C expression in ischemic white matter lesions. 54 61
18261165 2008
17
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 54 61
18548143 2008
18
Association of blood pressure and genetic background with white matter lesions in patients with mild cognitive impairment. 54 61
18511756 2008
19
New biochemical markers in acute coronary syndromes. 54 61
18537608 2008
20
PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. 54 61
17052804 2008
21
Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. 54 61
17420019 2007
22
Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. 54 61
17220293 2007
23
Polymorphisms in apolipoprotein B and risk of ischemic stroke. 54 61
17595251 2007
24
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 61 54
17534460 2007
25
Silent brain infarction and platelet activation in obstructive sleep apnea. 54 61
17341649 2007
26
Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. 54 61
17212611 2007
27
Delapril plus indapamide: a review of the combination in the treatment of hypertension. 54 61
17506588 2007
28
A perspective on telmisartan and cardiovascular risk. 61 54
17938615 2007
29
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. 61 54
17192928 2006
30
Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. 54 61
17054909 2006
31
Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. 54 61
16945218 2006
32
Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. 54 61
16894458 2006
33
Cognitive frailty: Predementia syndrome and vascular risk factors. 54 61
16023766 2006
34
Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. 54 61
16208431 2006
35
[The relationship between ApoE gene polymorphism and lipid parameters]. 54 61
16335008 2005
36
The spectrum of mutations for CADASIL diagnosis. 54 61
15995828 2005
37
Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. 54 61
16013194 2005
38
Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? 54 61
15662026 2005
39
Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. 61 54
15681302 2005
40
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephaloapthy (CADASIL): a hereditary cerebrovascular disease, which can be diagnosed by skin biopsy electron microscopy. 61 54
15798438 2005
41
T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. 54 61
15644279 2005
42
[Mutations of genes associated with thromboses in ischemic stroke in patients with primary antiphospholipid syndrome]. 61 54
16320685 2005
43
Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. 61 54
15858957 2005
44
The FABP2 gene polymorphism in cerebrovascular disease. 61 54
15527447 2004
45
RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. 61 54
15459432 2004
46
ACE genotype and cognitive decline in an African-Caribbean population. 61 54
15465635 2004
47
Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. 61 54
15361766 2004
48
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. 61 54
15471834 2004
49
Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. 54 61
15016346 2004
50
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. 54 61
15161326 2004

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.16 SERPINA3 MIR21 HTRA1 APP APOE APOB
2 extracellular region GO:0005576 10.11 SERPINA3 NOTCH3 HTRA1 CRP COL4A1 APP
3 collagen-containing extracellular matrix GO:0062023 9.89 SERPINA3 HTRA1 COL4A1 APOE APOA1
4 endoplasmic reticulum lumen GO:0005788 9.88 COL4A1 APP APOE APOB APOA1
5 high-density lipoprotein particle GO:0034364 9.61 APOE APOB APOA1
6 very-low-density lipoprotein particle GO:0034361 9.58 APOE APOB APOA1
7 endocytic vesicle lumen GO:0071682 9.5 APOE APOB APOA1
8 discoidal high-density lipoprotein particle GO:0034365 9.46 APOE APOA1
9 extracellular space GO:0005615 9.44 SERPINA3 SELP MIR21 HTRA1 CRP COL4A1
10 low-density lipoprotein particle GO:0034362 9.43 APOE APOB APOA1
11 chylomicron GO:0042627 9.33 APOE APOB APOA1
12 intermediate-density lipoprotein particle GO:0034363 9.13 APOE APOB APOA1

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.02 MIR21 CRP APP APOB ACTA2
2 cellular protein metabolic process GO:0044267 9.9 APP APOE APOB APOA1
3 positive regulation of inflammatory response GO:0050729 9.81 MIR21 APP AGTR1
4 platelet degranulation GO:0002576 9.78 SERPINA3 SELP APP APOA1
5 retinoid metabolic process GO:0001523 9.76 APOE APOB APOA1
6 cholesterol metabolic process GO:0008203 9.76 APP APOE APOB APOA1
7 intermembrane lipid transfer GO:0120009 9.7 APOE APOB APOA1
8 high-density lipoprotein particle assembly GO:0034380 9.63 APOE APOA1
9 phospholipid efflux GO:0033700 9.63 APOE APOA1
10 amyloid precursor protein metabolic process GO:0042982 9.62 APOE ACHE
11 methionine biosynthetic process GO:0009086 9.61 MTR MTHFR
12 high-density lipoprotein particle clearance GO:0034384 9.61 APOE APOA1
13 cholesterol efflux GO:0033344 9.61 APOE APOB APOA1
14 very-low-density lipoprotein particle remodeling GO:0034372 9.59 APOE APOA1
15 chylomicron remnant clearance GO:0034382 9.58 APOE APOB
16 lipoprotein metabolic process GO:0042157 9.58 APOE APOB APOA1
17 regulation of Cdc42 protein signal transduction GO:0032489 9.57 APOE APOA1
18 very-low-density lipoprotein particle clearance GO:0034447 9.56 APOE APOB
19 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.55 AGTR1 ACE
20 lipoprotein catabolic process GO:0042159 9.54 APOE APOB
21 low-density lipoprotein particle remodeling GO:0034374 9.54 APOE APOB AGTR1
22 positive regulation of amyloid fibril formation GO:1905908 9.51 APP APOE
23 negative regulation of long-term synaptic potentiation GO:1900272 9.5 CX3CR1 APP APOE
24 positive regulation of phospholipid efflux GO:1902995 9.49 APOE APOA1
25 chylomicron assembly GO:0034378 9.43 APOE APOB APOA1
26 chylomicron remodeling GO:0034371 9.33 APOE APOB APOA1
27 positive regulation of cholesterol esterification GO:0010873 9.13 APOE APOA1 AGTR1
28 lipoprotein biosynthetic process GO:0042158 8.8 APOE APOB APOA1

Molecular functions related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.62 SELP APP APOE APOB
2 amyloid-beta binding GO:0001540 9.61 APOE APOA1 ACHE
3 lipid transporter activity GO:0005319 9.43 APOE APOB APOA1
4 lipoprotein particle binding GO:0071813 9.4 APOE APOA1
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.37 APOE APOA1
6 bradykinin receptor binding GO:0031711 9.16 AGTR1 ACE
7 low-density lipoprotein particle receptor binding GO:0050750 9.13 CRP APOE APOB
8 intermembrane cholesterol transfer activity GO:0120020 8.8 APOE APOB APOA1

Sources for Cerebrovascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....